跳转至内容
Merck
CN

PZ0271

醋酸PF-06463922

≥98% (HPLC)

别名:

(10R).7-氨基-12-氟-2,10,16-三甲基-15-氧代-10,15,16,17-四氢-2H.8,4-(甲基)吡唑并[4,3.h ] [2,5,11]-苯并二氮杂二环十四癸-3-乙酸乙腈, 醋酸洛拉替尼

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C21H19FN6O2 · CH3COOH
化学文摘社编号:
分子量:
466.46
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

醋酸PF-06463922, ≥98% (HPLC)

SMILES string

CC(O)=O.NC1=C(O[C@@H](C2=C3C=CC(F)=C2)C)C=C(C4=C(C#N)N(C)N=C4CN(C)C3=O)C=N1

InChI

1S/C21H19FN6O2.C2H4O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12;1-2(3)4/h4-7,9,11H,10H2,1-3H3,(H2,24,25);1H3,(H,3,4)/t11-;/m1./s1

InChI key

BLNAIBLTPYGILH-RFVHGSKJSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 10 mg/mL, clear

storage temp.

room temp

Quality Level

Application

PF-06463922乙酸已被用作间变性淋巴瘤激酶(ALK)的抑制剂,从而通过qPCR对肾上腺髓质素的表达进行分析。

Biochem/physiol Actions

PF-06463922是变性淋巴瘤激酶(ALK)和c-ros癌基因1(ROS1)的一种有效的选择性脑可穿透抑制剂,其对在克唑替尼耐药的患者中发现的所有已知ALK和ROS1突变体均具有很强的活性。PF-06463922正被用于治疗非小细胞肺癌(NSCLC)的临床试验中。

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Shana Claeys et al.
Oncotarget, 8(63), 106820-106832 (2018-01-02)
Neuroblastoma is an aggressive childhood malignancy of the sympathetic nervous system. Despite multi-modal therapy, survival of high-risk patients remains disappointingly low, underscoring the need for novel treatment strategies. The discovery of Here, we further dissected the transcriptional dynamic profiles of
Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome
Shana Claeys
Oncotarget (2017)
Liying Chen et al.
The Journal of clinical investigation, 128(1), 446-462 (2017-12-05)
Pharmacologically difficult targets, such as MYC transcription factors, represent a major challenge in cancer therapy. For the childhood cancer neuroblastoma, amplification of the oncogene MYCN is associated with high-risk disease and poor prognosis. Here, we deployed genome-scale CRISPR-Cas9 screening of

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持